Despite solid cash flow from Vyjuvek, the gene therapy developer is neglecting R&D investments. The potential consequences are being ignored by investors and Wall Street.

Despite whiffing on revenue guidance for half of 2024, management came out swinging once again. Full-year 2025 revenue guidance calls for record growth of 61%.

The business delivered its first operating profit since Q2 2023. Strong software revenue is powering the business – and it's about to get even stronger thanks to the Chemaxon acquisition.

Commercial execution remains the surest path to salvation. Although I don't assign a high value to the company's pipeline at this time, the second-most advanced asset could provide a meaningful catalyst in 2025.

The company's prized asset delivered a no-doubter data readout that crushed prior-gen comparisons, but Scorpion Therapeutics quickly cemented itself as a next-gen competitor.

Revenue has more than doubled since the beginning of fiscal 2022. However, the number of customers has only grown by 28% in that span. There are advantages and disadvantages to the trend.

The new premium offerings, which boast a faster turnaround time than the company's standard synthetic genes, surged the order backlog of the synthetic genes segment to $44.9 million – an increase of 54% from the fiscal first quarter.

The DNA synthesis leader is growing revenue at a solid clip and improving operating efficiency. Although operating income is a distant milestone, Express Genes should accelerate its arrival.